ST. PAUL, Minn., May 11, 2017 /PRNewswire/ -- EnteroMedics Inc.
(NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity, metabolic diseases and
other gastrointestinal disorders, will host a conference call on
Tuesday, May 16, 2017 at 8:30 AM Eastern Time to discuss results for the
first quarter ended March 31, 2017
and to provide an update on the commercialization of
vBloc® Neurometabolic Therapy.
Conference Call Details
The first quarter conference call may be accessed by dialing
(877) 280-7473 (U.S. and Canada)
or (707) 287-9370 (international), and entering passcode 22425310.
A replay of the call will be available from May 16, 2017 at 2:00 PM
Eastern Time through May 23,
2017 at 2:00 PM Eastern Time
by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and
entering passcode 22425310.
To access the live webcast, visit the events page of the
investor relations section of EnteroMedics' website at
www.enteromedics.com. A replay of the webcast will be available
immediately after the conference call.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of its neuroscience based
technology to treat obesity and metabolic diseases.
vBloc® Neurometabolic Therapy, delivered by a
pacemaker-like device called the vBloc® System, is
designed to intermittently block the vagus nerves using
high-frequency, low-energy, electrical impulses. EnteroMedics'
vBloc® System has received U.S. Food and Drug
Administration approval and CE Mark.
Information about the vBloc® System and
vBloc® Neurometabolic Therapy
You should not have an implanted vBloc® System if you
have cirrhosis of the liver, high blood pressure in the veins of
the liver, enlarged veins in your esophagus or a significant hiatal
hernia of the stomach; if you need magnetic resonance imaging
(MRI); if you have a permanently implanted, electrical medical
device; or if you need a diathermy procedure using heat. The most
common related adverse events that were experienced during clinical
study of the vBloc System included pain, heartburn, nausea,
difficulty swallowing, belching, wound redness or irritation, and
constipation.
Talk with your doctor about the full risks and benefits of vBloc
Therapy and vBloc System. For additional prescribing information,
please visit www.enteromedics.com.
If you are interested in learning more about vBloc
Neurometabolic Therapy, please visit www.vbloc.com or call
1-800-MY-VBLOC.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-to-host-first-quarter-2017-conference-call-300455783.html
SOURCE EnteroMedics Inc.
